EUROPEAN RESPIRATORY JOURNAL

The demise of DIP, and the way forward
Mukhopadhyay S and Sansano I
Novel pathomechanisms of ventilator-induced neonatal lung injury: new targets to overcome ongoing challenges
Ehrhardt H, Staude B and Abman SH
Preserving conceptual clarity: why hypersensitivity pneumonitis should remain a separate entity from bronchiolocentric interstitial pneumonia
Selman M and Buendía Roldán I
Substituting bronchiolocentric interstitial pneumonia for hypersensitivity pneumonitis: a word of caution
Raghu G, Remy-Jardin M, Lynch DA and Myers JL
Reply: Bronchiolocentric interstitial pneumonia is a morphological term used for lung biopsy and chest imaging pattern and is not a substitute for hypersensitivity pneumonitis
Ryerson CJ, Adegunsoye A, Piciucchi S, Hariri LP, Khor YH, Wijsenbeek MS, Wells AU, Sharma A, Cooper WA, Antoniou K, Borie R, Fabre A, Inoue Y, Johannson KA, Johkoh T, Kawano-Dourado L, Kazerooni E, Maher TM, Molyneaux PL, Protti R, Ravaglia C, Renzoni EA, Saito-Koyama R, Sverzellati N, Walsh SLF, Wolters PJ, Yang SR, Travis WD and Nicholson AG
Reply: The rationale for distinguishing RB-ILD and AMP
Piciucchi S, Adegunsoye A, Travis WD, Nicholson AG, Wells AU, Cooper WA, Khor YH, Wijsenbeek MS, Sharma A, Hariri LP, Antoniou K, Borie R, Fabre A, Inoue Y, Johannson KA, Johkoh T, Kawano-Dourado L, Kazerooni E, Maher TM, Molyneaux PL, Protti R, Ravaglia C, Renzoni EA, Saito-Koyama R, Sverzellati N, Walsh SLF, Wolters PJ, Yang SR and Ryerson CJ
The expanding and accelerating universe of bronchiectasis
Martinez-Garcia MA and Soriano JB
Cooling the flames, clearing the airways: systemic inflammation in the era of elexacaftor/tezacaftor/ivacaftor
Seo C and Thornton CS
Challenges in harmonising terms and patterns among interstitial pneumonias: enter idiopathic bronchiolocentric interstitial pneumonia
Fernández Pérez ER
Classification of interstitial pneumonias: ready for the future or stuck in the past?
Kolb M, Cottin V and Crestani B
Enhancing SABRE's clinical utility in idiopathic pulmonary fibrosis: addressing methodological concerns
Zhang Z, Wu Y and Zou Y
Reply: SABRE for airway quantification in idiopathic pulmonary fibrosis: clarifications, limitations, and next steps
Nan Y, Felder F, Walsh S and Yang G
https://bit.ly/3VVacfK
Quantitative airway biomarkers in idiopathic pulmonary fibrosis: SABRE's promise, validation gaps, and the road to clinical adoption
Zhang T
Whole lung directed anti-muscarinic therapy improves small airway dysfunction in COPD patients
Usmani OS, Toumpanakis D, Meah S, Mak V and Biddiscombe MF
Long-term efficacy but rare sustained remission: Individual-level five-year stability in anti-IL5/Rα biologic therapy response for severe asthma
Håkansson KEJ, Hansen S, Soendergaard MB, von Bülow A, Hilberg O, Bonnesen B, Johnsen CR, Lock-Johansson S, Dongo L, Borup MB, Vijdea R, Rasmussen LM, Schmid JM, Ulrik CS, Porsbjerg C and Bjerrum AS
For a decade, anti-Interleukin 5/Receptor alpha (IL5/Rα) has been available for severe asthma, with marked reductions in exacerbation rates and maintenance oral corticosteroid (mOCS) burden. However, little is known about the long-term, real-world sustained remission. We aimed to assess the stability of response to anti-IL5/Rα over five years.
Advances in cystic fibrosis: CFTR modulator triple combinations
Burgel PR and Mall MA
Reduced lung fluid club cell secretory protein informs chronic lung allograft dysfunction risk
Rim JG, Weber JM, Neely ML, O'Grady N, Kelly FL, Myers RA, Nagler A, McArthur P, Frankel CW, Belperio JA, Budev M, Hartwig MG, Martinu T, Reynolds JM, Shah PD, Singer LG, Snyder LD, Weigt SS, Palmer SM and Todd JL
Lung transplant recipients with lower club cell secretory protein (CCSP) levels in the bronchoalveolar lavage fluid (BALF) early posttransplantation are at increased risk for chronic lung allograft dysfunction (CLAD). For CLAD risk stratification, we previously identified a potential risk threshold for reduced CCSP (protein-normalized CCSP <8.63 ng·µg). Here, we aim to validate this association in an independent patient set from a prospective observational cohort.
Impact of positive airway pressure therapy on pulmonary artery pressures in obstructive sleep apnea or obesity hypoventilation syndrome: a systematic review and meta-analysis
Mokhlesi B, Hache-Marliere M, Bjork ST, Jain D, Malhotra A, Jimenez JFM and Labarca G
There is limited and conflicting evidence on the impact of obstructive sleep apnea and its treatment with positive airway pressure (PAP) therapy on pulmonary hypertension (PH).
Shared pathways, shared risks: the overlap of interstitial lung abnormalities and coronary heart disease
Podolanczuk AJ and Miller CL
Reply to: Enhancing methodological rigour in meta-analyses of renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Meservey A, Feng R, Kawut SM and Moutchia J
Lower lobe mucus plug distribution and future respiratory exacerbations in tobacco-exposed individuals with and without COPD
Wan ES, Borgaonkar R, Mettler S, Nardelli P, Iturrioz-Campo M, Manapragada PP, Abozeed M, Aziz MU, Zahid M, Grumley S, Yen A, Sonavane S, Wang W, Cho MH, San José Estépar R and Diaz AA